@unusual_whales Very cool, Apple. This could be transformative for the DS community. @brianskotko, curious to hear your thoughts about how this could be leveraged for more regular screenings.
Grateful for the opportunity to share new insights into the impact of longer treatment with NurOwn on NfL and to be surrounded by passionate individuals dedicated to finding treatments for ALS. Can’t think of a better way to spend the morning.
@StacyLindborg what a great presentation. Wonderful feedback from the community. Now we’re going to listen to @MaryKayTurner1 and @KylanMorris1 together with @layneo5 about patients experience with selecting clinical trials.
@KylanMorris1@LesTurnerALS@MeritCudkowicz Looks like an amazing evening, worthy of celebrating @MeritCudkowicz and Dr. Lidsky. Congratulations also to the amazing organization, @LesTurnerAL. I hope it was a productive gala, which will further your mission.
The @US_FDA granted $BCLI a positive Special Protocol Assessment (SPA) for this trial and formally agreed that the design and planned analysis for our phase 3b trial adequately address the objectives necessary to support a regulatory approval. https://t.co/RoUanpny8r
Largely unreported, SEC has made an unannounced policy shift where they treat many Reverse Mergers like "shell" deSPACs (not as typical mergers), which hampers ability of newly public co to finance & locks up affiliates far longer. May materially change +/-'s for Reverse Mergers
BrainStorm Cell Therapeutics Announces Outcome of FDA Meeting on NurOwn® in #ALS. Meeting Provided a Clear Path for Planned Phase 3b Trial. https://t.co/ZM5gX2hFMI